Antic, Darko
Milic, Natasa
Chatzikonstantinou, Thomas
Scarfò, Lydia
Otasevic, Vladimir
Rajovic, Nina
Allsup, David
Alonso Cabrero, Alejandro
Andres, Martin
Baile Gonzales, Monica
Capasso, Antonella
Collado, Rosa
Cordoba, Raul
Cuéllar-García, Carolina
Correa, Juan Gonzalo
De Paoli, Lorenzo
De Paolis, Maria Rosaria
Del Poeta, Giovanni
Dimou, Maria
Doubek, Michael
Efstathopoulou, Maria
El-Ashwah, Shaimaa
Enrico, Alicia
Espinet, Blanca
Farina, Lucia
Ferrari, Angela
Foglietta, Myriam
Lopez-Garcia, Alberto
García-Marco, José A.
García-Serra, Rocío
Gentile, Massimo
Gimeno, Eva
da Silva, Maria Gomes
Gutwein, Odit
Hakobyan, Yervand K.
Herishanu, Yair
Hernández-Rivas, José Ángel
Herold, Tobias
Itchaki, Gilad
Jaksic, Ozren
Janssens, Ann
Kalashnikova, Olga B.
Kalicińska, Elżbieta
Kater, Arnon P.
Kersting, Sabina
Koren-Michowitz, Maya
Labrador, Jorge
Lad, Deepesh
Laurenti, Luca
Fresa, Alberto
Levin, Mark-David
Mayor Bastida, Carlota
Malerba, Lara
Marasca, Roberto
Marchetti, Monia
Marquet, Juan
Mihaljevic, Biljana
Milosevic, Ivana
Mirás, Fatima
Morawska, Marta
Motta, Marina
Munir, Talha
Murru, Roberta
Nunes, Raquel
Olivieri, Jacopo
Pavlovsky, Miguel Arturo
Piskunova, Inga
Popov, Viola Maria
Quaglia, Francesca Maria
Quaresmini, Giulia
Reda, Gianluigi
Rigolin, Gian Matteo
Shrestha, Amit
Šimkovič, Martin
Smirnova, Svetlana
Špaček, Martin
Sportoletti, Paolo
Stanca, Oana
Stavroyianni, Niki
Te Raa, Doreen
Tomic, Kristina
Tonino, Sanne
Trentin, Livio
Van Der Spek, Ellen
van Gelder, Michel
Varettoni, Marzia
Visentin, Andrea
Vitale, Candida
Vukovic, Vojin
Wasik-Szczepanek, Ewa
Wróbel, Tomasz
Segundo, Lucrecia Yáñez San
Yassin, Mohamed
Coscia, Marta
Rambaldi, Alessandro
Montserrat, Emili
Foà, Robin
Cuneo, Antonio
Carrier, Marc
Ghia, Paolo
Stamatopoulos, Kostas
Article History
Received: 19 April 2022
Accepted: 8 August 2022
First Online: 26 August 2022
Declarations
:
: Mentioned in the manuscript.
: Not applicable.
: L.S. received advisory boards fees from AbbVie and Janssen; educational activity AstraZeneca. DA received funding to attend symposia from Gilead and Bayer. MA received advisory boards fees from AbbVie, AstraZeneca, Janssen-Cilag; travel support from AbbVie and Novartis. RC received speaker fees from Roche, Janssen, AbbVie, AstraZeneca, Celgene, BMS, Kite, and Takeda; advisory board fees from Janssen, AbbVie, Celgene, BMS, Kite, Takeda, Incyte, Kyowa-Kirin, and ADCT; travel and accommodation expenses from Roche, Janssen, AbbVie, Celgene, BMS, Kite, Takeda, and Pfizer; research grant from Pfizer. MC received honoraria from AbbVie, Gilead, Janssen, and AstraZeneca. LS received advisory boards fees from AbbVie, BeiGene and Janssen; educational activity AstraZeneca. BE received consulting or advisory boards fees from Janssen, Roche, Novartis, AbbVie, Gilead, Celgene, ArQule, AstraZeneca, Oxford Biomedica (UK), and BeiGene; speaker / speaker’s bureau fees from Janssen, Gilead, Roche, AbbVie, Novartis, Celgene, Adaptive Biotechnologies, BioGene, and AstraZeneca; research support / research funding from Janssen, Gilead, Roche, AbbVie, BeiGene, and AstraZeneca; travel, accommodations, expenses from Janssen, Roche, Novartis, AbbVie, Gilead, and Celgene. MF received honoraria from Abbvie, Janssen, Gilead. JAG-M received honoraria for advisory board and speaker´s bureau from Mundipharma, Glaxo, AbbVie, Roche, Gilead, AstraZeneca, and Janssen; research support from Hoffman-La Roche, AbbVie, and Janssen. RG-S received educational grants from AbbVie, Janssen, and Novartis. EG received travel grants, honoraria as a consultant and/or speaker bureau for Janssen-Cilag, Roche, and AbbVie. MGDS received honoraria for consultancy/advisory boards with Roche, Janssen Cilag, Gilead, AbbVie, and BMS; research Grant from Gilead, and AstraZeneca. YH received honoraria from AbbVie, Janssen, AstraZeneca, Roche and Medison, outside the submitted work. JAH received honoraria and advisory boards fees from Janssen, AbbVie, AstraZeneca, Roche, Beigene, Gilead, and BMS-Celgene. OJ received honoraria from AbbVie, Janssen, and Roche. AK received honoraria from Janssen, BMS, Astra Zeneca, Roche/Genentech; research money from Janssen, BMS, AstraZeneca, and Roche/Genentech. SK received Travel grant from Celgene; research funding from Janssen, Roche/Genentech, and AbbVie. LL received honoraria for advisory board and lecturing from Janssen, Gilead, AbbVie, Roche, and AstraZeneca. M-DL received advisory board and travel expenses from AbbVie, Janssen, Takeda, and Roche. AG received speaker’s bureau fees from Roche, Janssen, AbbVie, Celgene, Fresenius, Novonordisk; advisory board participation fees from Janssen, and AbbVie; travel and accommodation expenses from Roche, Janssen, and AbbVie. MoMa received speaker bureau fees from Amgen, honoraria as a consultant from Gilead. JM received honoraria and travel grants from AbbVie, Janssen, Roche, Gilead, and Takeda. JAHR received honoraria and advisory boards fees from Janssen, Abbvie, AstraZeneca, Roche, Beigene, Lilly, Gilead, and BMS-Celgene. MD received honoraria from AbbVie, Janssen, Astra-Zeneca, and Novartis. FRM received research funding from Gilead; advisory board participation fees from AbbVie, Gilead, Janssen, AstraZeneca, Takeda, and Roche; speakers bureau fees from Gilead, Janssen, and AbbVie. TM received honoraria from AbbVie, Janssen, AstraZeneca, Gilead, Roche, and Alexion; advisory board participation fees from AbbVie, AstraZeneca, Janssen, Alexion, Morphosys, and Sunesis. RM received honoraria from Janssen, AbbVie, and AstraZeneca. MAP received advisory board participation fees from Janssen, AbbVie, Astra Zeneca, and Merck; speaker’s bureau fees from Janssen, AbbVie, AstraZeneca, Varifarma, and Merck. FMQ received advisory board participation fees from Astrazeneca, and Janssen; speakers bureau fees from AstraZeneca, and Janssen; consultant (but no fees) for Sandoz; travel accommodation from Amgen and Gentili. GR received consultancy fees and honoraria from Abbvie, AstraZeneca, and Janssen. MaMo received consultancy fees from Gilead srl. GMR received honoraria from AbbVie, Gilead, and Janssen; received research funding from Gilead. MS received consultancy fees, advisory board participation fees, travel grants, honoraria from Janssen, Gilead, Roche, AstraZeneca, AbbVie. MS received honoraria from AbbVie, AstraZeneca, Gilead, Janssen, and Roche. PS received funding from Gilead; advisory board participation fees from AbbVie and Janssen; honorarium AbbVie, Janssen, and AstraZeneca. SEA received speaker fees from Janssen, and Takeda. LT received advisory board participation fees from Janssen, Roche, AbbVie, Gilead, Takeda; research funding from Janssen, Roche, Takeda, and Gilead. EVDS received teaching activities fees from Amgen; speaker fees from Janssen. MV received advisory board participation fees from Janssen, Roche, Astra Zeneca, Beigene; speaker fees from Abbvie. AJ received consultancy fees from AstraZeneca, Janssen, Novartis, and Sanofi; advisory board participation fees from Astra Zeneca, Janssen, Sobi, Novartis, Sandoz, MSD, and Incyte, Beigene; speaker fees from Astra Zeneca, Janssen, Sobi, Incyte, Novartis, Abbvie, Amgen, Takeda, and Beigene. AE received honoraria and advisory boards fees from Janssen, Abbvie, Novartis, Biosidus and BMS-Celgene. AV received speaker’s bureau fees from Italfarmaco and Gilead; advisory board participation fees from Janssen and Takeda. CV received honoraria from Janssen. IM received speaker Fees from Janssen, Roche, Abbvie, Sandoz. FM received fees from Janssen, and Gilead. TW received research funding from Roche; honoraria for advisory board, and research funding from Janssen; honoraria, advisory board participation fees, and travel grant from AbbVie; speaker’s bureau fees from Gilead. TC, AK, GK, AAC, DA, MB, MBG, AC, SC, J-GC, CC-G, LDP, MRDP, GDP, CD, MD, DD, ME, MKM, LF, AF, MoF, MG, OG, YKH, TH, II, GI, OBK, EK, JLG, DL, EL, LM, RM, MaMa, MaMot, RN, JO, LO, MP, IP, VMP, GQ, RR, JGC, SS, GS, AS, OS, NS, TT, DTR, ST, MVG, EWS, MY, AR have no conflict of interest to disclose.